Most active pharmaceutical ingredients (APIs) in the U.S. are made overseas, which can create supply chain vulnerabilities, security concerns, and prolonged shortages. A new manufacturing approach powered by wheat germ could help expand API production in the U.S., produce manufacturing efficiencies, and drive innovative technologies that enable distributed pharmaceutical manufacturing.
What’s at stake
Developing a better, faster, and cheaper manufacturing process using wheat germ cell-free expression systems employed in API manufacturing processes could help U.S. manufacturers make a range of essential medicines that stabilize and reshore API production in the U.S., reducing reliance on foreign countries for critical ingredients and decreasing potential supply chain disruptions.
A new manufacturing approach powered by wheat germ could help U.S. producers make biologics and small-molecule drugs more quickly, efficiently, and affordably.
